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Abstract: Vaccine-preventable diseases are global mainly in a globalized world that is characterized
by a continuous movement of people and goods across countries. Vaccine hesitancy, the reluctance
or refusal to vaccinate despite the availability of vaccines, is rising worldwide. What if the problem
of vaccine hesitancy could be most effectively managed when treated globally rather than on a
national or regional basis? What if a global vaccine-hesitant segment exists and the differences among
countries are not so significant? Based on the Global Marketing Strategy paradigm, this paper shows
that seven different cross-European segments exist based on the beliefs, attitudes, and behaviors
collected in 28 European countries. These pan-European segments are differentiable (people in those
segments have similar characteristics that are visibly dissimilar from the ones in other segments)
and actionable (organizations would be able to propose interventions to the hesitant segments based
on their profiles). With segmentation being the starting point of many public health intervention
strategies for avoiding vaccine-hesitancy, the results recommend moderating the full-adaptation
strategy that follows the “context matters” principle suggested by several political and public health
international organizations. Embracing a more standardized strategy will allow the development of
better services and strategies that support and enable desirable vaccination behaviors.
Keywords: vaccine hesitancy; segmentation; social marketing
1. Introduction
Vaccine hesitancy—the reluctance or refusal to vaccinate despite the availability of
vaccines- is rising worldwide. Even though vaccines are considered one of the most
important achievements of public health, preventing an estimated 2.5 million deaths
each year worldwide and reducing disease-specific treatment costs [1], the World Health
Organization (WHO) identified vaccine hesitancy as one of the top ten global health threats
of 2019 [2].
Vaccine hesitancy is not a new trend. Since 1795, when Edward Jenner published the
book titled “An Inquiry into the Cowpox”, vaccination has become a mainstream medical
practice all over the world [3]. Nevertheless, from their beginnings, inoculations have
had their detractors. The earliest ones were men of the church. They reasoned that
infectious diseases were a God-given fact of life and death. Some medical doctors, those
that were earning a lot of money from useless but lucrative cures, also enrolled in the
anti-vaccination movement early [3]. Vaccination was associated with diverse hazards
including tuberculosis, cancer, madness, blood poisoning, and syphilis [4]. From the middle
of the 19th century, Great Britain and the countries under its influence made vaccination
compulsory. Parents that refused to inoculate their children were sent to prison. The results
were disastrous, with social riots that ended with the abolishment of the acts that made
vaccination compulsory in 1909. The lessons provided by these first experiences were clear:
the risks of vaccination must not be silenced, and compulsory vaccination was not the
answer to the lack of public confidence in vaccines.
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Nowadays, vaccine doubters are increasing in number. In several Western countries,
diseases that had nearly been eradicated are coming into sight again due to their vaccine
rates weakening. Vaccine refusal has been increasing in many EU member states [5]. Be-
tween 2000 and 2019, the uptake of measles-containing-vaccine first-dose has decreased in
12 EU member states [6]. Moreover, 14 EU member states were below the immunization
rate threshold of 95% that was required to achieve herd immunity in 2019 [7]. The same
situation could be found in seasonal influenza and other infectious diseases [5]. The last
episode of vaccine hesitancy is related to the COVID-19 pandemic. Some people are afraid
that the pace of both scientific review and vaccine control could compromise safety. Differ-
ences in acceptance rates rage enormously from country to country around the world [8,9].
Governments, public health officials, pharmacy companies, and other stakeholders are
worried about people’s willingness to receive vaccines when appropriate [10].
Vaccine-preventable diseases are global in nature. National immunization programs
would benefit from coordinated analysis, action, and control to combat cross-border health
threats [11]. In order to avoid the negative consequences of the vaccine hesitancy across
the general population, it is necessary, first, to determine population sub-groups that adopt
that behavior and, second, to reduce any fear or concern and manage the demand for
vaccines [12]. Organizations such as governments and public health services face their
particular bundle of distinctive challenges. Based on the premise that context matters,
the scientific literature has mostly identified a set of key processes that could overcome
hesitancy barriers and would enhance vaccine uptake on a nation-by-nation basis [13].
What if the problem of vaccine hesitancy could be most effectively managed when treated
globally rather than on a national or regional basis? What if a global vaccine-hesitant
segment exists and the differences among countries are not so significant?
Independent of the pro-vaccination strategy to follow, audience targeting and seg-
mentation strategy are the keys to success [13]. People’s attitudes, values, and observed
behaviors are the basis to obtain insights for better targeting the intervention mix to maxi-
mize vaccine uptake [14]. Organizations that work in worldwide markets face the dilemma
of whether to segment markets on a country-by-country basis or to treat the different
segments that exist with adapted value propositions, or whether to target one or more
similar segments in a standardized way with the same intervention mix—also known as
cross-market segmentation—[15]. Public health has used health education, health promo-
tion, and social marketing as effective tools for influencing behavior in the fight against
several communicable and non-communicable diseases [16]. Identifying global vaccination
segments, to the extent that they exist, would allow designing and implementing a more
efficient and effective public health intervention strategy, since cross-country segments
would be targetable with similar activities.
To the best of our knowledge, the Global Marketing Strategy (GMS) paradigm has not
been applied to fight against infectious diseases by supranational political institutions and
health organizations. GMS proposes that a global organization must standardize its market-
ing programs across countries as much as possible, mainly concerning its product offering,
promotional mix, price, and channel structure [17]. Most of the guidelines that international
and national health organizations and governments suggest following when designing
a social marketing vaccination strategy are not global [16,18–22]. Based on the principle
of “context matters”, they suggest that different countries must design and implement
marketing plans adapted to their “unique” characteristics. It means they have adopted the
traditional form of international segmentation known as a multidomestic strategy. Several
researchers argue that global marketing strategy plays a critical role in determining an
organization’s performance in the global market [17,23–25]. Hence, these international
political institutions and health organizations that do not apply—or recommend not to
apply—the GMS paradigm could be achieving suboptimal outcomes on developing better
services and strategies that support and enable desirable vaccination behaviors.
The standardized strategy accompanying the GMS approach enhances performance
in sectors in which competition is global in scope [17]. These major benefits are mainly
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obtained through economies of scale and scope, consistency in dealing with the target
groups, and the ability to exploit good ideas at a global scale. The global pharmaceutical
industry produces vaccines. The pharmaceutical industry is comprised of some major
multinational companies operating in a highly global competitive market that has experi-
enced significant growth during the past two decades. Pharmaceutical revenues worldwide
totaled USD 1.25 trillion in 2019 [26]. Vaccine hesitancy is also fueled by misinformative
campaigns promoted by political, religious, and social organizations on a global scale [27].
Misinformation leads to mistrust in public health organizations and encourages antiscience
sentiments [28]. This fake information is transmitted worldwide at lightning speed in
a single click. Responding to the global threat posed by vaccine hesitancy with local
intervention actions seems not to be enough.
This study is designed to answer two research questions. The first is to confirm
whether there are homogeneous segments based on vaccination attitudes, beliefs, and
behaviors across European countries. Cross-national segmentation is challenging when
cultural and economic differences influence customer preferences [29]. Our study, which
analyzes cross-national market segments of individuals with respect to the acceptance of
vaccination in 28 European member countries, provides valuable insights into international
political and health organizations, companies, practitioners, and academics. The second
question is whether the pan-European segments that exhibit higher hesitancy are differen-
tiable (the people in those segments should have similar needs that are visibly dissimilar to
the needs of the people in other segments) and actionable (organizations have to be able to
propose interventions to the hesitant segments).
2. Materials and Methods
The data comes from the EUROBAROMETER survey 91.2 that was carried out between
the 15th and the 29th of March 2019, at the request of the European Commission [30]. The
dataset was accessed through GESIS (Leibniz-Institute für Sozialwissenschaften, University
of Cologne, Germany). The EUROBAROMETER is part of wave 91.2 and covers the
population of the respective nationalities of the European Union member states, residents
in each of the member states, and aged 15 years and over. In these countries, the survey
covers the national population of citizens of the respective nationalities and the population
of citizens of all the European Union member states that are resident in those countries
and have a sufficient command of one of the respective national language(s) to answer the
questionnaire. The basic sample design applied in all states is a multi-stage random one.
The following table (Table 1) shows the sample size in each country and the total
population aged 15 or more years.
Table 1. Sample size by country, Total population 15+.
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Table 1. Cont.




















United Kingdom 1021 52,651,777
TOTAL 27,524 431,452,219
Source: Eurobarometer 91.2. European Commission [30,31] Table A1 (Appendix A) shows the variables selected
from this Eurobarometer to perform the analysis and the sample statistical descriptives.
For answering whether cross-European vaccination segments exist based on vaccina-
tion attitudes, beliefs and behaviors, we applied a factor-cluster segmentation approach.
We selected all the variables shown in Table A1. From the 46 variables, 44 were coded as
binary, and 2 as polytomous (the one that asked if “vaccines are effective” and the one that
asked “the most trusted info source”). For performing the correct association matrix for the
factor analysis—using tetrachoric or polychoric correlations, when appropriate—we used
the “polycor” package from R [32]. Aiming to reduce the complexity of the observed data
to a more limited set of components and to avoid multicollinearity problems, we computed
a principal component analysis (PCA) using the “psych” package from R. Zero frequency
cells were replaced by 0.5 considering Yate’s correction for continuity [33]. Using the scores
for the resulting components, we clustered them choosing the best clustering method
between hierarchical methods, K-Means, and PAM considering three internal measures of
clustering validation: Connectivity, Dunn, and Silhouette. Attending to the compactness,
separation, connectivity, and interpretability of the solution, we chose the optimal number
of segments, described and labeled them. For testing whether the pan-European segments
that exhibit higher hesitancy were differentiable, we calculated segments’ means differences
applying an ANOVA (Tukey HSD). To check if the found segments were cross-European,
we ran a Bayesian multilevel multinomial analysis. Once we confirmed that there were
no differences between countries for the clustering solution, we performed a multinomial
logit regression for testing the actionability of the segments. For better interpreting these
results, we used marginal effects.
3. Results
PCA analysis results are shown in Table A2 (Appendix B). To determine the number
of components we ran a parallel analysis [34] using the “psych” package from R. The
results of the parallel analysis suggested that 14 components explaining 66% of the to-
tal variance might be most appropriate—RMSR = 0.05 and fit based upon off-diagonal
values = 0.94–0.0.
For interpreting the components, we used the Varimax rotated component analysis
matrix depicted in Table A2 (Appendix B). Our cutoff point for interpretation purposes was
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all loadings ±0.4 or above [35–37]. Considering the loadings, we named the components
as depicted in Table 2.
Table 2. Principal Components Analysis (Varimax Rotation).
Component # 1
Component
Name 1 Original Variables with Significant Loadings
Percentage of
Total Variance
C1 Vaccines not important
Vaccines important
9%
Vaccines are rigorously tested before being
authorized for use
Everybody needs to have routine vaccinations
Not getting vaccinated can lead to serious
health issues
Vaccines are important to protect not only yourself
but also others
Vaccination of other people is important to protect
those that cannot be vaccinated
C2 Infectious diseases kill
Flu is causing deaths in the EU nowadays
8%
Measles is causing deaths in the EU nowadays
Polio is causing deaths in the EU nowadays
Hepatitis is causing deaths in the EU nowadays
Meningitis is causing deaths in the EU nowadays
Tetanus is causing deaths in the EU nowadays
C3 Vaccines are dangerous
Vaccines overload and weaken the immune system
5%
Vaccines can cause the disease against which
they protect
Vaccines can often produce serious side-effects
Do not know at which level vaccination programs
should be coordinated
C4 Vaccine informed
Seen vaccine info in the last six months on TV
6%
Seen vaccine info in the last six months on the radio
Seen vaccine info in the last six months in
newspapers or magazines
Seen vaccine info in the last six months on online
social networks
Seen vaccine info in the last six months on other
Internet sites
C5 Children vaccinated
Have a vaccination card for children
5%Children vaccinated in the last five years
C6 Family & friends info
If you were looking for information about
vaccination, you would consult family
3%If you were looking for information about
vaccination, you would consult friends
C7 European vaccination
programs
Vaccination programs should be coordinated at
European level
4%Vaccination programs should be coordinated at a
national level
Vaccination programs should be coordinated at a
regional or local level








If you were looking for information about
vaccination NONE of the following sources you
would consult
4%If you were looking for information about
vaccination DO NOT KNOW which of the following
sources you would consult
Family is the source you trust the most for
information on vaccination
C9 Other sources of info
If you were looking for information about
vaccination, you would consult other sources
of information 3%
In the past six months, you have seen, read or heard
any information on vaccination in other media
C10 Health system info
If you were looking for information about
vaccination, you would consult other health care
workers (nurses, specialist doctors, etc.)
3%If you were looking for information about
vaccination, you would consult pharmacists
If you were looking for information about
vaccination, you would consult the
health authorities
C11 Self-vaccinated
I got vaccinated in the last five years
4%I have a vaccination card
Tend to agree that not getting vaccinated can lead to
serious health issues
C12 Vaccination lack of knowledge
Do not know if you or someone in your family had
any vaccinations in the last five years
4%
Do not know if you have a vaccination card
Do not know if you were looking for information
about vaccination, which of the following sources
would you consult
Do not know if in the past six months you have seen,
read or heard any information on vaccination in
the media
C13 Online media info
If you were looking for information about
vaccination you would consult online
social networks
4%
If you were looking for information about
vaccination you would consult other Internet sites
In the past six months you have seen, read or heard
information on vaccination on online
social networks
In the past six months you have seen, read or heard




You think vaccination programs should be
coordinated at an international level 3%
You have a vaccination card
1 The fourteen components obtained were labeled in two different ways. First, with a capital C followed by a number (Component #). This
is the name given by R software when using the “psych” library for performing PCA analysis. We maintained these original names without
any change for research reproducibility reasons. The other name of each the components were given in the need for obtaining a substantive
interpretation of the pattern of the component loadings for the variables. Variables with higher significant factor loadings influenced the
name selected to represent a factor to a greater extent [38].
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In sum, we obtained 14 components out of the 44 original variables that explained 66%
of the total variance. The two most important ones, in terms of the total variance explained
individually, were related to the belief that infectious diseases kill (C2, 8% of the total
variance) and vaccines are important to fight them (C1, 9% of the total variance). On the
other hand, if we consider all the components that were connected with the information (C4,
C6, C8, C9, C10, and C13) summed up the highest proportion of the total variance explained
(23%). The rest of the components could also be gathered into three different groups: the
first connected with the vaccination status (C5 and C11, 9% of the total variance); the
second related to the knowledge about vaccines (C3) and vaccination (C12), which together
explained 9% of the total variance; and, finally, two components (C7 and C14) linked with
the international level at which the vaccination programs should be managed (7% of the
total variance explained).
Using the factor scores for each of the fourteen components obtained in the previous
step for all the interviewees, we proceeded to analyze the different behavioral segments
that existed towards vaccination in the European Union. For choosing the best clustering
method we used the package “clValid” from R [39]. Hierarchical methods performed
better than K-Means and PAM for the three internal measures of clustering validation
used (Connectivity, Dunn, and Silhouette). Considering the compactness, separation,
connectivity, and interpretability, the seven-cluster solution performed the best. Figure 1
depicts the results of the hierarchical clustering approach (using the squared Euclidean
distance and the Ward method). The characteristics of each of the found segments were:
1. Pro-Vaccinators (55.7% of the sample). It was the most numerous European segment.
Following the segment profile represented in Figure 1, people for whom vaccines were
the most important for avoiding the negative effects of infectious diseases formed it
(in Table A3, Appendix C, we saw that mean differences with all the other segments
were statistically significant). It belonged to the group of segments that answered
that they felt better informed about vaccines, but the information received was highly
insecure. Attending to how the “Information insecurity” component was composed,
we saw that it had three significant loadings—the answers “None (SPONTANEOUS)”
and “DK” to the question “If you were looking for information about vaccination,
which of the following sources would you consult?”, and the high importance of the
option “Family” when responding the question “And which of the following sources
do you trust the most for information on vaccination?”—It portrays a component
with the family as the most important source of information about vaccination, under
the feeling of insecurity about any information source related to this issue. All the
fake news that is present in the information environment is affecting the perception of
knowledge, even in the pro-vaccinators segment. Insecurity about information affects
the perception of knowledge. Therefore, the Europeans that belonged to this segment
had the lowest scores on knowledge about vaccines and vaccination. They were
vaccinated in the last five years. Their most preferred source of information was the
Health System Info. They agreed that either European or international organizations
should manage vaccination programs globally.
2. Self-hesitants (14.2% of the sample). It was the second segment that made a point on
jabs to avoid infectious diseases. They shared a profile with Pro-vaccinators in relation
to the information: they had information but not knowledge about vaccines, and
were not personally vaccinated due to information insecurity. They had no doubts
about their child’s vaccination (see in Figure 1 that they had the highest score of
all segments) but they did when they were inoculated. That was why they were
labeled as “Self-hesitants”. Their favored source of information was Online Media
Info, followed by the Health-System Info. They agreed that vaccination programs
should be managed by international organizations, with the European authorities
being the most preferred ones.
3. Social-hesitants (9.6% of the total sample). This segment displayed a medium-range
position on the importance of vaccines in avoiding infectious diseases. The respon-
Vaccines 2021, 9, 617 8 of 28
dents replied having been inoculated in the past five years at the same level as the
Pro-vaccinators but their hesitance affected their child’s vaccination. They declared
themselves to be informed but with a feeling of lack of knowledge about vaccines and
vaccination. This led them to information insecurity. They did not trust Online Media
Info nor Health System Info preferring, by far, their relatives as the main information
source. That is why we called them Social-hesitants. They slightly preferred that in-
ternational organizations managed the vaccination programs instead of the European
authorities.
4. Anti-vaccinators (11.7% of the sample). They showed the lowest confidence in vac-
cines of all the segments. They declared themselves to be well informed and with top
knowledge on vaccines but not on vaccination. They did not feel insecure about the in-
formation received. Their unconfident belief caused them not to be open about taking
vaccines, but they did not show the same behavior for their children. Their preferred
sources of information were Online Media Info and Health System Info. A remarkable
characteristic of this segment was that they did not trust international organizations
for managing the vaccination programs, mainly favoring the European ones.
5. Alternative-hesitants (2.5% of the sample). The hesitancy for this group was mainly
based on the lack of confidence in Online Media Info and Health System Info. Oth-
erwise, they felt comfortable with Family and Friends Info and showed an absolute
preference for Other Sources of Info. In consequence, the reported information in-
security was also high. They portrayed a lack of knowledge about vaccines and
vaccination. They shared with the other hesitant groups the lack of confidence in
vaccines but, surprisingly, they and their children were among the top segments that
had taken vaccines in the last five years.
6. Illiterate-hesitants (4% of the sample). This group share with other hesitants their
lack of confidence in vaccines. Their most noteworthy characteristic is that they
declared themselves not to be well informed about vaccines. Their vaccination status
in the past five years was in the medium range of all groups. The most liked source
of information was the Health System Info, closely followed by Online Media Info
and Family and Friends. They showed a complete lack of confidence in international
organizations when managing the vaccines’ programs. European authorities were
also not well considered.
7. Uninformed Anti-Vaccinators (2.3% of the sample). The first distinctive attribute is
that they had the lowest score in vaccine trust. Accordingly, they showed the lowest
score in believing that infectious diseases kill. They declared themselves to be vaccine
informed and to have an average knowledge on vaccines. Nonetheless, they had an
absolute lack of knowledge about vaccination. The insecurity felt by this group about
the information received was also the highest of all the segments found. It was so
high that they did not trust any source of information. They rather preferred that
the international organization would manage the vaccination programs. All these
sentiments produced low vaccination rates among their children.
For answering the question of whether countries affected the results obtained we ran a
Bayesian multilevel multinomial analysis using STAN [40]. The dependent variable was the
one with the resulting segments (reference category: Pro-Vaccinators) and as independent
variables, we considered each of the fourteen principal components obtained. In doing
so, we checked to what extent did the log-odds varied between countries computing an
unconditional mean model and calculating the intraclass correlation coefficient (ICC). The
parameters used for running the Hamiltonian Monte Carlo sampler algorithm (MCMC)
were 2500 warmup iterations, 4 chains, 10,000 iterations per chain, and initials values taken
at random. The solution converged (Rhat = 1.0) and the results are shown in Table 3.
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Table 3. Bayesian Multilevel Multinomial Analysis. Unconditional Mean Model (log-odds).
Posterior Mean 1 Posterior SD 2 Rhat 3
Population-level effects (reference
category: Pro-vaccinators)
Intercept Self-hesitants −1.38 0.07 1.0
Intercept Social-hesitants −1.85 0.11 1.0
Intercept Anti-vaccinators −1.63 0.12 1.0
Intercept Alternative-hesitants −3.20 0.11 1.0
Intercept Illiterate-hesitants −2.90 0.17 1.0
Intercept Uninformed
Anti-vaccinators −3.54 0.21 1.0
Country-level effects (reference category:
Pro-vaccinators)
Intercept Self-hesitants 0.33 0.05 1.0
Intercept Social-hesitants 0.58 0.09 1.0
Intercept Anti-vaccinators 0.63 0.09 1.0
Intercept Alternative-hesitants 0.55 0.09 1.0
Intercept Illiterate-hesitants 0.89 0.14 1.0
Intercept Uninformed
Anti-vaccinators 1.07 0.17 1.0
1 Mean of the posterior distribution using MCMC. 2 Standard deviation of the posterior distribution using MCMC.
3 Rhat is the potential scale reduction factor on split chains (at convergence, Rhat = 1).
The ICC quantifies the degree of homogeneity of the outcome within countries. The

























refers to the standard
logistic distribution, that is, the level-1 variance component. The ICC may range from 0 to 1.
ICC = 0 indicates perfect independence of residuals: The chance to pertain to a behavioral
segment does not depend on country membership. However, ICC = 1 indicates perfect
interdependence of residuals: The segment’s membership only varies between countries.
Calculating, we obtained ICC= 0.095. In other words, it means that between countries the
differences in the segmentation achieved are negligible. Due to this reason, we performed
a multinomial logit model for calculating the relationship between the segments and the
principal components found (see Table 4).
From Table 4, we noticed that most of the independent variables—the principal
components—are statistically significant in explaining the European segments. To improve
the interpretability of the regression coefficients, we used marginal effects. The marginal
effect is a measure of the instantaneous effect that a change in a particular explanatory vari-
able has on the predicted probability of the dependent variable when the other covariates
are kept fixed [41]. The dependent variable is modeled as follows:
y = E(y/x) + ε, (2)
where E(y/x) is the conditional mean function, x is the vector of explanatory variables and






where F denotes a cumulative distribution function and β denotes the parameters. Therefore,
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where f (.) is the density function that corresponds to the cumulative function F(.). The
marginal effects are nonlinear functions of the parameter estimates and levels of the
explanatory variables. Hence, they generally cannot be inferred directly from parameter
estimates. In this case, we used the R library called “margins”. The results are available in
Appendix D, Figures A1–A14.
Table 4. Cross-European Segments Towards Vaccination. Multinomial Logit Model (log-odds).












−0.088 0.593 *** 2.475 *** 2.037 *** 1.899 *** 3.135 ***
−0.058 −0.07 −0.055 −0.419 −0.215 −0.396
C2
−0.498 *** 0.05 −0.488 *** −0.076 0.619 *** 0.454
−0.041 −0.053 −0.044 −0.486 −0.231 −0.438
C3
0.308 *** 0.194 *** 1.141 *** 1.257 *** 1.591 *** 0.875 ***
−0.049 −0.062 −0.046 −0.393 −0.194 −0.309
C4
−0.262 *** −0.249 *** −0.611 *** −0.691 −2.597 *** −1.617 ***
−0.039 −0.056 −0.05 −0.555 −0.273 −0.554
C5
2.845 *** 0.157 *** 0.538 *** −0.644 0.198 0.171
−0.043 −0.051 −0.043 −0.663 −0.23 −0.464
C6
−0.569 *** 3.694 *** −0.146 * 0.912 ** 0.673 *** −3.979 ***
−0.067 −0.065 −0.077 −0.428 −0.223 −1.352
C7
−0.180 *** −0.800 *** −3.637 *** −1.922 *** −1.843 *** −1.129 **
−0.045 −0.062 −0.063 −0.498 −0.222 −0.441
C8
0.06 −0.720 *** 0.151 ** 0.925 0.221 3.880 ***
−0.057 −0.076 −0.068 −0.59 −0.321 −0.435
C9
−0.337 *** 0.537 *** 0.465 *** 5.333 *** 0.301 −0.702
−0.106 −0.138 −0.123 −0.446 −0.515 −0.792
C10
−0.264 *** −0.165 ** −0.729 *** −1.181 * −0.014 −3.343 ***
−0.043 −0.068 −0.05 −0.608 −0.301 −0.761
C11
−0.378 *** −0.101 ** −0.359 *** −0.224 −0.851 *** −1.261 **
−0.033 −0.045 −0.039 −0.472 −0.225 −0.514
C12
0.214 ** 0.033 0.607 *** 4.421 *** 6.999 *** 0.699
−0.107 −0.141 −0.111 −0.382 −0.346 −0.48
C13
0.546 *** −0.456 *** −0.425 *** −0.773 −0.704 *** −3.534 ***
−0.037 −0.056 −0.048 −0.487 −0.248 −1.045
C14
−0.366 *** −0.468 *** −1.092 *** −1.366 *** −2.323 *** −1.013 **
−0.036 −0.048 −0.041 −0.373 −0.202 −0.409
Constant
−3.303 *** −3.934 *** −3.039 *** −9.268 *** −8.875 *** −12.241 ***
−0.065 −0.083 −0.06 −0.687 −0.541 −1.153
Note: * p < 0.05, ** p < 0.01, *** p < 0.001.
By simultaneously interpreting the data contained in Table 4 and Figures A1–A14, we
obtained the following results. Pro-Vaccinators and Anti-Vaccinators had differentiated
profiles. Furthermore, the predicted probability for belonging to one of these groups
showed an inverted shape in the case of “Vaccines Not Important” (Figure A1), “Infec-
Vaccines 2021, 9, 617 12 of 28
tious Diseases Kill” (Figure A2), “Vaccines Informed” (Figure A3), “Vaccine Knowledge”
(Figure A5), “‘Self Vaccinated” (Figure A8), “European Vaccination Programs” (Figure A9),
“Health System Info” (Figure A12), and “International Vaccination Programs” (Figure A14).
Self-Hesitants shared with Anti-Vaccinators the aforementioned reversed profile with
Pro-Vaccinators in the case of “Infectious Diseases Kill” (Figure A2), “Vaccines Informed”
(Figure A3), “Self Vaccinated” (Figure A8) and “Health System Info” (Figure A12). More-
over, this inverted predicted probability profile between Self-Hesitants and Pro-Vaccinators
was also present in the variables “Children Vaccinated” (Figure A4) and “Online Media
Info” (Figure A10). Illiterate-Hesitants depicted their main differential characteristic with
Pro-Vaccinators in the variable “Vaccination Lack of Knowledge” (Figure A6). The main
portrayed difference between Uninformed Anti-Vaccinators and Pro-Vaccinators arose in
the component “Information Insecurity” (Figure A7). Social-Hesitants and Pro-Vaccinators
differed markedly in “Family and Friends Info” (Figure A11). Finally, the main differential
characteristic between Alternative-Hesitants and Pro-Vaccinators rose in ‘Other Sources
Info’ (Figure A13). These results corroborated the findings commented when previously
describing the behavioral segments’ profiles in Figure 1.
4. Discussion
In the previous section, we have presented results that allow answering the two main
research questions proposed. First, based on vaccination attitudes, beliefs and behaviors
there exist seven different homogeneous segments across the European countries. These
pan-European segments are differentiable and actionable.
In a recent report based on a descriptive analysis of the same survey that we used in
this paper, the European Commission stated that “ . . . While in general Europeans have a
reasonably high level of awareness and a generally positive attitude towards vaccination,
there is considerable variation in knowledge and behavior across countries and between
socio-demographic groups” [42] (p. 59). The results in the previous section of this paper
depicted that cross-European segments based on attitudes towards vaccination existed.
When European countries were considered in order to see if there were any significant
variation between them in the segments obtained, we concluded that it was not the case.
The geographical differences found by the European Commission could be rather linked to
the different proportions in which the cross-European segments were represented in each
of the member countries than the non-existence of these homogeneous groups. It can be
graphically appreciated in Figure 2. It shows a MOSAIC chart [43] that can be interpreted,
in a two-way table, as a grouped bar chart where the width of each bar corresponds to
the relative frequencies of the first variable (number of interviews per country) and the
height of each bar shows the relative frequencies of the second variable (European segments
towards vaccination). Standardized residuals are represented in the chart by shadowing the
tiles: those that exceed values 2 and 4 in absolute terms are deep-colored. When it occurs,
it means that the found pattern departures from the Equiprobability model (independence
between the variables). Statistically speaking, it means that, as the standardized residuals
are approximately unit-normal N(0,1), the shadowed areas are those whose individual
residuals are significant at 0.05 level (when the value exceeds 2) and 0.0001 level (when the
value exceeds 4) [44]. For the shake of clarity, we observe in Figure 2 that Pro-Vaccinators
had a statistically significant higher presence in Belgium, the Netherlands, the United
Kingdom, Spain, Portugal, Finland, Sweden, Malta, and Slovenia. On the contrary, Pro-
Vaccinators showed a statistically significant lower presence in Austria, Czech Republic,
Estonia, Latvia, Poland, Slovenia, Bulgaria, Romania, and Croatia. On the other side of
the attitudes’ spectrum, Anti-Vaccinators had a statistically significantly higher presence
in France, Luxembourg, Austria, Czech Republic, Estonia, Latvia, Lithuania, Bulgaria,
Romania, and Croatia. In contrast, Belgium, the Netherlands, Denmark, Spain, Portugal,
Finland, Sweden, Hungary, and Poland had a statistically significantly lower presence
of Anti-Vaccinators. The rest of the segments and countries could be distinctly exhibited
in Figure 2. The differences observed by the European Commission between European
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countries in their descriptive analysis are due to the different share that the seven cross-
European segments had in each of the territories. Nevertheless, the profile of any of the
individuals that belong to a segment remains homogeneous to the rest of the individuals
that also pertain to the same segment, independently of the European country under study.
The seven segments obtained overcome the traditional pro-vaccine versus anti-vaccine
approach. Between these two extreme poles, five other vaccine-hesitant behaviors were
found. As we have seen, the individuals that comprised these segments can retard, be
averse but still uptake, or decline some or all vaccines. Furthermore, the process followed
to obtain the segments avoided the negative connotations associated with the terms “anti-
vaccine” and “vaccine-hesitant”. When conducting research about vaccine hesitancy we
have to take into account that even those individuals that present the most radical profile
do not recognize themselves as “anti-vaccine” [45]. Thus, in the survey that we used, the
individuals were first asked about beliefs, attitudes, and behaviors about vaccines and
vaccination, and then, after applying sound statistical techniques, we found the segments
that were labeled taking into account their different profiles.
From the private companies’ management perspective, the findings presented are
important. Infectious diseases are global by their nature, mostly in a global economy
characterized by a continuous flow of goods and persons between countries. The pharmacy
industry and vaccines are also global [46]. Therefore, only if different client behaviors exist
that are profitable for the private companies to fulfill with adapted marketing strategies, it
would be justified not to follow a Global Marketing Strategy (GMS) approach. Nowadays,
for instance, there is more convergence in demand for newer vaccine types and more
divergence in demand for mature and combination vaccine types. For the latter ones,
adaptations to existing vaccine presentations and packaging are required and increasingly
requested. Manufacturers benefit from these distinct presentations, as they prevent parallel
trade between high-income countries and low-income countries enable manufacturers to
pursue multiple pricing strategies. The existence of cross-European vaccination segments
offers additional evidence for private companies when deciding on the continuum that
goes from the full standardization to the full adaptation of marketing strategy.
For social marketers (v.gr. European Commission, International Health Organizations,
governments, and health authorities), behavioral segmentation is key for success when
choosing the target audience and developing different marketing strategies for selected pop-
ulation segments. Social marketing has been long employed in designing, implementing,
and evaluating public health programs in the fight against several forms of communicable
diseases [47–49]. Moreover, the GMS approach remains valid: adaptation is mainly rec-
ommended when there are behavioral differences between the segments that when taken
into action produce better results. Our Bayesian multilevel multinomial analysis showed
that there were no statistically significant differences for the clusters when considering the
28 countries that formed the European Union. Hence, public organizations that apply a
standardized marketing strategy across countries will obtain better outcomes [17,23–25].
The Anti-Vax industry is applying these standardized marketing strategies in their disin-
formation campaigns obtaining better results than the public institutions that are fighting
against them with adapted marketing actions [50].
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Information is key in both the understanding of the vaccine up-taking decision process
and the characterization of the different segments around vaccination. From the results
obtained, we noticed that the components related to the different sources of information
summed up the highest proportion of the total variance explained (23%). From Table A1 we
knew that the most trusted source of information was a general practitioner, a doctor, or a
pediatrician (79.1% of the total responses). Several investigations showed that a significant
share of health care providers is vaccine-hesitant [51–55]. Even though few health care
providers are openly against vaccines, many of them find conversations about vaccines
with vaccine-hesitant people to be difficult and unproductive [52]. This has to be a matter
of concern for public health authorities. The results of our research also showed that some
segments declare a lack of knowledge around vaccines and/or vaccination (Uninformed
Anti-Vaccinators and Social-Hesitants). Fighting against the lack of knowledge has to be a
priority as a starting point. Nevertheless, lessening the growth of vaccine hesitancy requires
not only to communicate information about vaccine efficacy and safety but engaging
with the problems expressed by the citizens in an empathically two-way communication
strategy [56,57]. Furthermore, it also means sending the tailored messages through the right
communication channels. As we saw in the Results section, Pro-Vaccinators and Illiterate-
Hesitants preferred the Health system info, Self-Hesitants and Anti-Vaccinators favored
social media Info, Social-Hesitants chose their relatives as the main information source,
Alternative-Hesitants indicated other sources of information and, finally, Uninformed
Anti-Vaccinators felt such high insecurity about the information received that they did not
place trust in any source of information.
Trust in international organizations positively influences people’s willingness to adopt
recommended behavior [58,59]. As we saw, the level of trust in the international organi-
zations to carry on the vaccination programs varied among segments. Pro-vaccinators
trusted in European as well as international organizations for managing vaccination pro-
grams. Self-Hesitants and Alternative-Hesitants preferred the European ones. Reversely,
Social-Hesitants and Uninformed Anti-Vaccinators favored International Organizations.
Anti-Vaccinators and Illiterate-Hesitants did not trust any international organization in the
management of the vaccination programs, mainly the European ones. Therefore, depend-
ing on the target audience, the source of the tailored communication campaign has to be
adequately selected to be trusted.
Once that we know that global vaccine hesitancy segments exist across, Europe some
other challenges arise. For instance, in Europe immunization programs are a national
competence with vaccination schedules that vary across the different territories. We
face the GMS dilemma of global consumers with local organizations. The European
Commission and the Member States need to put in place coordinated operational guidelines
for overcoming infrastructural and legal barriers through more standardized vaccination
management. In this regard, two European initiatives taken in 2018 [11,60] accomplished
an actions’ framework that was undertaken by the Commission, with the collaboration of
the Member States, under three key pillars: (1) tackling vaccine hesitancy and improving
vaccination coverage; (2) sustainable vaccination policies in the EU; (3) EU coordination of
and contribution to global health. The roadmap for the implementation of actions contained
in these two European initiatives fixes several challenges that a global social marketing
strategy for reducing vaccine hesitancy must face because immunization programs are a
national competence.
Finally, more study is required to understand the effect that age, gender, family status,
occupation, education, type of community where the person lives, political orientation,
and religion have in the cross-European segments found and the proposed GMS strategy.
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Appendix A
Table A1. Sample descriptives.
Variable # 1 Variable Response Categories n Sample Share
qc1
Diseases causing








None of them 2348 8.5
Don’t Know (DK) 1728 6.3
qc2 Vaccines effective
Yes, definitely 13,972 50.8
Yes, probably 9450 34.3
No, probably not 1664 6
No, not at all 870 3.2
It depends on the disease 1011 3.7
Don’t Know (DK) 557 2
qc3 Vaccinations in familylast five years
Yes, yourself 11,820 42.9
Yes, your children 7164 26
Yes, someone else 5521 19.1
No 9683 35.2
Don’t Know (DK) 315 1.1
qc6 Have vaccination card
Yes, for yourself 11,754 42.7
Yes, for your children 6813 24.8
No 11,978 43.5
Don’t Know (DK) 651 2.4
qc7_1 Vaccines affect theimmune system
TRUE 8849 32.2
FALSE 14,461 52.5
Do not Know (DK) 4214 15.3
qc7_2 Vaccines cause diseases
TRUE 10,669 38.8
FALSE 13,066 47.5








Don’t Know (DK) 2904 10.6
qc8_1 Routine vaccinationimportant
Totally agree 14,222 51.7
Tend to agree 8776 31.9
Tend to disagree 2670 9.7
Totally disagree 890 3.2
Don’t Know (DK) 966 3.5
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Table A1. Cont.
Variable # 1 Variable Response Categories n Sample Share
qc8_2 Vaccines only for
children
Totally agree 3643 13.2
Tend to agree 4551 16.5
Tend to disagree 8351 30.3
Totally disagree 10,270 37.3
Don’t Know (DK) 709 2.6
qc8_3 Not vaccinated serious
health issues
Totally agree 13,065 47.5
Tend to agree 9371 34
Tend to disagree 3008 10.9
Totally disagree 932 3.4
Don’t Know (DK) 1148 4.2
qc8_4 Vaccines’ importance
for self and others
Totally agree 15,284 55.5
Tend to agree 8956 32.5
Tend to disagree 1819 6.6
Totally disagree 577 2.1
Don’t Know (DK) 888 3.2
qc8_5 Vaccines’ importance
for non-vaccinated
Totally agree 14,505 52.7
Tend to agree 9296 33.8
Tend to disagree 1786 6.5
Totally disagree 598 2.2
Don’t Know (DK) 1339 4.9
qc9 Vaccine info sources
Family 2627 9.5
Friends 1351 4.9
Your general practitioner, a doctor, or
a pediatrician 21,765 79.1
Other health care workers (nurses,
specialist doctors, etc.) 8647 31.4
Pharmacists 5103 18.5
Online social networks 1632 5.9
Other Internet sites 3539 12.9
The health authorities 7570 27.5
Other (SPONTANEOUS) 298 1.1
None (SPONTANEOUS) 504 1.8
Don’t Know (DK) 238 0.9




Your general practitioner, a doctor, or
a pediatrician 17,521 63.7
Other health care workers (nurses,
specialist doctors, etc.) 2695 9.8
Pharmacists 928 3.4
Online social networks 285 1
Other Internet sites 553 2
The health authorities 3323 12.1
Other (SPONTANEOUS) 74 0.3
None (SPONTANEOUS) 576 2.1
Don’t Know (DK) 369 1.3
qc11 Vaccine programs’
coordination level
At international level 8911 32.4
At European level 8399 30.5
At a national level 4526 42.4
At regional or local level 2512 9.1There should be no vaccination
programs, it is a personal choice
Don’t Know (DK) 1305 4.7
qc12 Media info on vaccine
last six months
No 8052 29.3
Yes, on TV 15,447 56.1
Yes, on the radio 4775 17.3
Yes, in newspapers or magazines 5771 21
Yes, on online social networks 3571 13
Yes, on other Internet sites 2835 10.3
Other (SPONTANEOUS) 433 1.6
Don’t Know (DK) 490 1.8
1 We kept the question number used in the Eurobarometer in order to be easily identifiable in the original questionnaire codebook. Source:
Eurobarometer 91.2. European Commision [30].
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Self-hesitants/Pro-vaccinators 0.05 ** −0.08 *** −0.03 1.82 *** 0.10 *** 0 −0.01
Social hesitants/Pro-vaccinators 0.27 *** 0.02 0.04 0.28 *** 0.04 −0.12 *** 0.22 ***
Anti-vaccinators/Pro-vaccinators 1.08 *** −0.08 *** −0.04 0.32 *** 0.35 *** −0.29 *** −0.40 ***
Alternative hesitants/Pro-vaccinators 0.35 *** −0.05 −0.27 *** 0.37 *** 0.05 −0.08 ** 0.14 ***
Illiterate hesitants/Pro-vaccinators 0.40 *** −0.05 −0.4 *** 0.24 *** 0.20 *** 3.00 *** 0.05
Uninformed
anti-vaccinators/Pro-vaccinators 1.58 *** −0.13 ** 0.02 0.13 *** 0.14 ** −0.67 *** 2.84 ***
Social hesitants/Self-hesitants 0.21 *** 0.09 *** 0.06* −1.55 *** −0.06 −0.12 *** 0.23 ***
Anti-vaccinators/Self-hesitants 1.03 *** 0.00 −0.01 −1.5 *** 0.25 *** −0.29 *** −0.39 ***
Alternative hesitants/Self-hesitants 0.30 *** 0.03 −0.24 *** −1.45 *** −0.05 −0.08 * 0.15 ***
Illiterate hesitants/Self-hesitants 0.35 *** 0.03 −0.37 *** −1.59 *** 0.10 * 3.00 *** 0.06
Uninformed anti-vaccinators/Self-hesitants 1.53 *** −0.05 0.05 −1.69 *** 0.04 −0.67 *** 2.85 ***
Anti-vaccinators/Social hesitants 0.82 *** −0.09 *** −0.08 ** 0.04 0.31 *** −0.16 *** −0.62 ***
Alternative hesitants/Social hesitants 0.08 −0.06 −0.31 *** 0.09 0.01 0.04 −0.09
Illiterate hesitants-Social hesitants 0.14 *** −0.07 −0.44 *** −0.04 0.16 3.13 *** −0.17 ***
Uninformed anti-vaccinators/Social
hesitants 1.32 *** −0.14 *** −0.02 −0.15 *** 0.1 −0.55 *** 2.61 ***
Alternative hesitants/Anti-vaccinators −0.073 *** 0.03 −0.23 *** 0.05 −0.30 *** 0.20 *** 0.53 ***
Illiterate hesitants-Anti-vaccinators −0.68 *** 0.02 −0.36 *** −0.08 * −0.15 *** 3.29 *** 0.45 ***
Uninformed
anti-vaccinators/Anti-vaccinators 0.50 *** −0.05 0.06 −0.19 * −0.21 *** −0.38 *** 3.23 ***
Illiterate hesitants/Alternative hesitants 0.05 0.00 −0.13 * −0.13 *** 0.15 * 3.08 *** −0.09
Uninformed anti-vaccinators/Alternative
hesitants 1.23 *** −0.08 0.29 *** −0.24 ** 0.09 −0.59 *** 2.70 ***
Uninformed anti-vaccinators/Illiterate
hesitants 1.18 *** −0.08 0.42 *** −0.11 *** −0.06 −3.67 *** 2.78 ***
Self-hesitants/Pro-vaccinators −0.34 *** 0.01 0.24 *** −0.07 *** −0.13 *** −0.04 *** −0.14 ***
Social hesitants/Pro-vaccinators 0 −0.13 *** −0.23 *** 2.15 *** −0.30 *** −0.04 *** −0.05
Anti-vaccinators/Pro-vaccinators −0.14 *** −1.09 *** 0.06 * 0.05 *** 0 −0.07 *** −0.21 ***
Alternative hesitants/Pro-vaccinators −0.04 −0.07 −0.22 *** 0.34 *** −0.13 ** 4.90 *** −0.11
Illiterate hesitants/Pro-vaccinators −0.20 *** −0.27 *** 0.13 *** 0.28 *** 0.15 *** −0.06 *** −0.69 ***
Uninformed
anti-vaccinators/Pro-vaccinators −0.01 −0.22 *** −0.81 *** −0.59 *** −1.47 *** −0.72 *** −0.01
Social hesitants/Self-hesitants 0.34 *** −0.14 *** −0.47 *** 2.23 *** −0.16 *** 0 0.10 **
Anti-vaccinators/Self-hesitants 0.20 *** −1.10 *** −0.18 *** 0.13 *** 0.13 *** −0.03 ** −0.07 *
Alternative hesitants/Self-hesitants 0.30 *** −0.08 −0.46 *** 0.42 *** 0 4.95 *** 0.03
Illiterate hesitants/Self-hesitants 0.14 ** −0.27 *** −0.11 ** 0.35 *** 0.28 *** −0.02 −0.54 ***
Uninformed anti-vaccinators/Self-hesitants 0.32 *** −0.22 *** −1.05 *** −0.51 *** −1.34 *** −0.67 *** 0.13 *
Anti-vaccinators/Social hesitants −0.14 *** −0.96 *** 0.29 *** −2.10 *** 0.30 *** −0.04 −0.17 ***
Alternative hesitants/Social hesitants −0.04 0.06 0.01 −1.81 *** 0.16 *** 4.94 *** −0.06
Illiterate hesitants-Social hesitants −0.20 *** −0.14 *** 0.35 *** −1.87 *** 0.45 *** −0.03 ** −0.64 ***
Uninformed anti-vaccinators/Social
hesitants −0.01 −0.09 −0.59 *** −2.74 *** −1.18 *** −0.68 *** 0.04
Alternative hesitants/Anti-vaccinators 0.11 1.02 *** −0.28 *** 0.29 *** −0.13 ** 4.98 *** 0.10
Illiterate hesitants-Anti-vaccinators −0.06 0.83 *** 0.07 0.23 *** 0.15 *** 0.01 −0.47 ***
Uninformed
anti-vaccinators/Anti-vaccinators 0.13 * 0.88 *** −0.87 *** −0.64 *** −1.47 *** −0.64 *** 0.20 ***
Illiterate hesitants/Alternative hesitants −0.17 ** −0.19 *** 0.35 *** −0.06 0.28 *** −4.97 *** −0.58 ***
Uninformed anti-vaccinators/Alternative
hesitants 0.02 −0.14 * −0.59 *** −0.93 *** −1.34 *** −5.62 *** 0.10
Uninformed anti-vaccinators/Illiterate
hesitants 0.19 ** 0.05 −0.94 *** −0.87 *** −1.63 *** −0.65 *** 0.68 ***
Note: * p < 0.05, ** p < 0.01, *** p < 0.001.
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